Related Experiment Video
Updated: Jul 9, 2026
10:10
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Effects of statins on platelet inhibition by a high loading dose of clopidogrel
Iris Müller1, Felicitas Besta, Christian Schulz
1Medizinische Klinik, Klinikum rechts der Isar und Deutsches Herzzentrum, Technische Universität München, Germany.
Circulation
|October 22, 2003
Summary
High-dose clopidogrel (600 mg) combined with statins did not inhibit antiplatelet effects. This study found no significant interaction between statins and clopidogrel, ensuring effective platelet inhibition.
Area of Science:
- Cardiovascular Pharmacology
- Platelet Aggregation Studies
Background:
- Concerns exist regarding statin-HMG-CoA reductase inhibitors potentially reducing clopidogrel's antiplatelet efficacy.
- Investigating statin-clopidogrel interactions is crucial for patients on dual antiplatelet therapy.
Purpose of the Study:
- To evaluate the impact of various statins on the antiplatelet activity of a high loading dose of clopidogrel.
- To determine if statin use affects clopidogrel's ability to inhibit platelet aggregation.
Main Methods:
- A randomized study involving 77 patients with stable angina undergoing coronary stenting.
- Patients received one of several statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, cerivastatin) or placebo, along with aspirin and a 600 mg clopidogrel loading dose.
- Adenosine diphosphate (ADP)-induced platelet aggregation was measured at baseline and 2 and 4 hours post-clopidogrel administration.
Main Results:
- None of the tested statins demonstrated a significant influence on the inhibition of platelet aggregation induced by clopidogrel.
- Platelet aggregation remained effectively inhibited across all statin groups and the placebo group.
Conclusions:
- Concurrent administration of statins with a high loading dose of clopidogrel (600 mg) does not significantly impair clopidogrel's antiplatelet activity.
- This finding suggests a safe co-administration of these common cardiovascular medications.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...